These findings provide support for clinical trials involving PI3K pathway inhibitors, tyrosine kinase inhibitors (TKIs) and MAPK pathway inhibitors in patients with cervical cancer detected by targeted molecular screening. This evidence concerns the gene PIK3CA and cervical carcinoma.